Biotrace taps into Scandinavia with Maltec buy
the healthcare sector with the acquisition of Denmark's Maltec,
helping it to target Scandinavia's strong pharma sector
UK microbiology company Biotrace has continued its expansion into the healthcare sector with the acquisition of Denmark's Maltec. The move provides Biotrace with a stronger presence in Scandinavia, one of its target territories, and also brings it into a region with a dense concentration of pharmaceutical companies.
While it has served the pharmaceutical industry for some years, Biotrace has embarked upon a concerted effort to expand its activities in the healthcare sector, most recently with last year's purchase of the UK's Fred Baker Scientific, now re-launched as Biotrace Fred Baker. This brought in a range of autoclaves, culture media and microbiological plasticware. Prior to this, in 2001, Biotrace acquired Congent, Ruskin and Toucan Technologies, the exclusive distributor of Ruskin-branded anaerobic and modified atmosphere cabinets in North America.
Biotrace has bought Maltec, which supplied Ruskin products in Scandinavia, for a token sum of £1. However, it also assumes the latter company's liabilities of DKK1.1 million (€148,000), including a director's loan of DKK700,000. Biotrace may also make an additional payment of £430,000 (€625,780) if Maltec business meets certain performance milestones. Maltec's founder, Malte Jacobsen, will continue to run the business.
Meantime, Biotrace Fred Baker has re-branded its environmental monitoring pre-prepared media, used in pharmaceutical environmental monitoring, under the Biotrace PPM banner.